Profound Medical Corp.
TSX:PRN.TOMedical - Devices
+$0.11 today
- Market cap
- $360.04M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.00M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Profound Medical Corp.
TSX:PRN.TO
Intrinsic Alpha fair value
Locked
Current Price
$9.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +34.8% | +53.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +34.8% over three years. Forward estimates point to Revenue at +53.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc. TSX:EPRX.TO | $783.37M | $11.65 | Not rated | -8.6 | +0.80% |
Auxly Cannabis Group Inc. TSX:XLY.TO | $365.45M | $3.54 | Overvalued | 7.3 | +2334.48% |
Medical Facilities Corporation TSX:DR.TO | $274.81M | $16.95 | Undervalued | 8.7 | +22.92% |
CareRx Corporation TSX:CRRX.TO | $204.24M | $3.22 | Undervalued | 7.4 | -4.18% |
HLS Therapeutics Inc. TSX:HLS.TO | $114.77M | $3.71 | Undervalued | -9.6 | -24.65% |
Continue the stock analysis
Jump to another research area for this company.